Evidence map›Paper›PMID 27699265›Full record

ArticleJCI insight2016

Targeting CLEC9A delivers antigen to human CD141

Kirsteen M Tullett, Ingrid M Leal Rojas, Yoshihito Minoda, Peck S Tan, Jian-Guo Zhang, Corey Smith, Rajiv Khanna, Ken Shortman, Irina Caminschi, Mireille H Lahoud and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. A single-shot vaccine approach for the universal influenza A vaccine candidate M2e.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  14. Article
  15. Dendritic cell-targeting chemokines inhibit colorectal cancer progression.Exploration of targeted anti-tumor therapy · 2022
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Kirsteen M TullettMater Research Institute - University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia.
Ingrid M Leal RojasMater Research Institute - University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia.
Yoshihito MinodaMater Research Institute - University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia.
Peck S TanInfection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia.
Jian-Guo ZhangThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Corey SmithQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Rajiv KhannaQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Ken ShortmanThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Irina CaminschiInfection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia.
Mireille H LahoudInfection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia.
Kristen J RadfordMater Research Institute - University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia.
Burnet Institute · AUMonash University · AUQIMR Berghofer Medical Research Institute · AUQueensland University of Technology · AUUniversity of Melbourne · AUUniversity of Queensland · AUWalter and Eliza Hall Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DC-based vaccines that initiate T cell responses are well tolerated and have demonstrated efficacy for tumor immunotherapy, with the potential to be combined with other therapies. Targeting vaccine antigens (Ag) directly to the DCs in vivo is more effective than cell-based therapies in mouse models and is therefore a promising strategy to translate to humans. The human CD141

Indexed as

ImmunotherapyMolecular Targeted TherapyAnimalsAntigensAntigens, SurfaceCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDendritic CellsHumansLectins, C-TypeMiceReceptors, MitogenThrombomodulinAntigensAntigens, SurfaceCLEC9a protein, humanLectins, C-TypeReceptors, MitogenTHBD protein, humanThrombomodulin

Identifiers

PMID27699265
PMCPMC5033826
OpenAlexW2403041597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.